Listed

Tempest Therapeutics, Inc.: Form 10-K for the period ended Dec 31, 2015

Filed with the SEC on Feb 26, 2016 and accepted by EDGAR at Feb 26, 2016, 17:33 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2015-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue12 months2015-01-01 to 2015-12-31$277.0kus-gaap:Revenues
Cost of revenue12 months2015-01-01 to 2015-12-31$2.2mus-gaap:CostOfRevenue
Research and development12 months2015-01-01 to 2015-12-31$18.4mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative12 months2015-01-01 to 2015-12-31$51.6mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income12 months2015-01-01 to 2015-12-31−$72.0mus-gaap:OperatingIncomeLoss
Income tax12 months2015-01-01 to 2015-12-31$75.0kus-gaap:IncomeTaxExpenseBenefit
Net income12 months2015-01-01 to 2015-12-31−$73.2mus-gaap:NetIncomeLoss
Diluted EPS12 months2015-01-01 to 2015-12-31−$2.70us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow12 months2015-01-01 to 2015-12-31−$50.3mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure12 months2015-01-01 to 2015-12-31$5.2mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2015-12-31$43.2mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2015-12-31$129.9mus-gaap:AssetsCurrent
Total assetsAt period end2015-12-31$138.6mus-gaap:Assets
Current liabilitiesAt period end2015-12-31$11.2mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2015-12-31$11.8mus-gaap:Liabilities
Shareholders' equityAt period end2015-12-31$126.8mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001544227-16-000008. Last ingested by Listed: Nov 15, 2026, 00:20 ET. Listed shows no prices and gives no investment advice.